Table 3. Reported incidence of adverse events by patient attributes.
| Characteristics | Attributes | n (N) | % (95%CI) | χ2 (Pvalue) |
|---|---|---|---|---|
| Enrolment | Main | 264 (4119) | 6.4 (5.6, 7.2) | 86.1(0.0001) |
| Nested | 83 (444) | 18.7 (15.1, 22.6) | ||
| Study Site | Navrongo | 175(1901) | 9.2 (7.9, 10.5) | 18.7(< 0.001) |
| Kintampo | 98 (1778) | 5.5 (4.4,6.6) | ||
| Dodowa | 74 (884) | 8.4 (6.6, 10.3) | ||
| Sex of Patients | Males | 151 (2185) | 6.9 (5.8, 8.0) | 2.9(0.094) |
| Females | 196 (2378) | 8.2 (7.1, 9.3) | ||
| Age groups (years) | < 6 | 157 (2201) | 7.1 (6.0, 8.2) | 22.6(<0.001) |
| 6–12 | 82 (1264) | 6.5 (5.1, 7.9) | ||
| 13–18 | 22 (369) | 6.0 (3.7, 8.8) | ||
| >18 | 86 (729) | 11.8 (9.5,14.3) | ||
| BMI (age 18 ≥ years) | Under | 19 (370) | 5.1 (3.1, 7.9) | 18.9(<0.001) |
| Normal | 57 (641) | 8.9 (6.8, 11.3) | ||
| Obese | 30 (184) | 16.3 (11.2, 22.4) | ||
| Concomitant medications during treatment | Yes | 288 (3938) | 7.3 (6.4, 8.1) | 3.5(0.062) |
| No | 59 (625) | 9.4 (7.2, 12.0) | ||
| Prior enrolment other medications | Yes | 82 (886) | 9.3 (7.4, 11.3) | 11.2(0.001) |
| No | 225 (3677) | 6.1 (5.3, 6.9) | ||
| Parasite density (μL) | < 50 | 24 (90) | 26.7 (17.8, 37.0) | 67.8(<0.001) |
| 50–499 | 55 (470) | 11.7 (8.9, 14.9) | ||
| 500–4999 | 47 (634) | 7.4 (5.4, 9.7) | ||
| 5000–49999 | 80 (1116) | 7.1 (5.6, 8.7) | ||
| ≥ 50000 | 56 (1107) | 5.1 (3.8, 6.5) |